San Francisco | U.S.A.
| Investor Type | Firm |
| Type of Fund | VC |
| Industries | Businesses Solutions • Life Science • Oncology |
| Stages | Seed |
| Investing | United States |
| Investment Range | $55,800,000 - $55,800,000 |
About The Fund
Aquilo Capital Management is a San Francisco-based venture capital firm specializing in transformative medicines and scientific breakthroughs within the biotechnology sector. Founded in 2010, they focus on investing in drug development companies that leverage cutting-edge science to address significant medical needs. They are committed to the discovery and development of paradigm-changing therapeutics that hold the promise of substantial risk-adjusted returns for the society, patients, and investors. Aquilo Capital Management combines deep sector expertise with a disciplined, value-oriented investment process. They have a strong emphasis on financial strength, allowing for a robust development strategy independent of the public equity market. Their investment approach includes an innovative platform for the continuous creation of differentiated drugs, a broad pipeline strategy to mitigate concentrated risk, and the fostering of strategic pharma partnerships which provide non-dilutive capital and validation for technologies. By having a diverse portfolio with multiple potential revenue streams, they ensure a margin of safety for their investments. Marc Schneidman, the founder and CIO, brings over 25 years of investing experience to the company. With a focus on both hedged and long-only investment strategies, the firm looks for opportunities with the potential to improve the practice of medicine. Their EU Opportunities initiative reflects an understanding of the unique research landscape in Europe, aiming to tap into innovative potential for efficient result delivery. Notably, Aquilo Capital Management has an investment size range with both minimum and maximum investment of $55,800,000. Their specialization is in seeding ventures and they operate as a venture capital fund. This firm's strategy and operations reflect a comprehensive approach to investing in and growing innovative biotech ventures with the ultimate goal of tackling large unmet medical needs and fostering industry growth.
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
e
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 85 Great Portland St.
- London, U.K.
- contact@angelspartners.com
